TY - JOUR T1 - A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. AU - Gras,Adrien, AU - Broughton,Julie, Y1 - 2016/02/26/ PY - 2016/1/12/pubmed PY - 2017/3/14/medline PY - 2016/1/12/entrez KW - Multiple sclerosis KW - pharmacoeconomics KW - resource utilization KW - spasticity KW - tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray KW - treatment costs SP - 771 EP - 779 JF - Expert review of pharmacoeconomics & outcomes research JO - Expert Rev Pharmacoecon Outcomes Res VL - 16 IS - 6 N2 - BACKGROUND: Severity of spasticity in multiple sclerosis (MS) directly correlates with the level and cost of care required. This study assessed whether a tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray for treatment of moderate-severe MS spasticity is a cost-effective use of healthcare resources in Wales. METHODS: A Markov model was developed to compare THC/CBD plus standard of care (SoC) treatments with SoC alone. RESULTS: At 30 years, total incremental cost for THC/CBD plus SoC treatment was estimated at £3,836/patient (ICER: £10,891/quality-adjusted life year [QALY]). Hospital admission costs had the greatest effect on the base case ICER. Inclusion of carer cost led to incremental cost of -£33,609/patient (ICER: -£95,423/QALY). CONCLUSIONS: The THC/CBD spray was found to be cost-effective for the treatment of spasticity in MS, and dominant, if home carer costs were included. Use of THC/CBD has the potential to generate cost savings by significantly improving the symptoms of moderate to severe MS spasticity. SN - 1744-8379 UR - https://www.unboundmedicine.com/medline/citation/26750641/A_cost_effectiveness_model_for_the_use_of_a_cannabis_derived_oromucosal_spray_for_the_treatment_of_spasticity_in_multiple_sclerosis_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737167.2016.1140574 DB - PRIME DP - Unbound Medicine ER -